- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01306279
The Infective Pulmonary Exacerbations in Cystic Fibrosis - an Ecological Perspective
Given the treatment burden and excess morbidity and mortality associated with acute infective exacerbations in cystic fibrosis, a clear understanding of the mechanisms involved in the origins of an infective exacerbation and the response to antibiotics is vital to improving long-term outcomes in CF.
This study will examine 3 areas of interest in CF exacerbations.
- Bacterial biodiversity and its clinical significance
- The role of bacteria which are able to rapidly mutate (hypermutators)
- Inter-bacterial communication and its role in infective exacerbations
Study Hypothesis 1
Increased microbiological diversity represents a balanced community of bacteria. The presence of a diverse population of bacteria in CF infections therefore predicts a better outcome for treatment than when a population consists of a small number of more virulent organisms.
Study Hypothesis 2
Pseudomonas aeruginosa hypermutators can mutate much more often than ordinary Pseudomonas aeruginosa bacteria. Hypermutators are likely to grow better when the bacteria are under stress, such as during antibiotic treatment or during an infection. They are, however, weaker organisms because of the multiple mutations they have undergone. Their presence does not relate to clinical outcome but may be associated with the emergence of antibiotic resistance.
Study Hypothesis 3
Some Pseudomonas aeruginosa bacteria communicate with each other by secreting and responding to chemicals known as quorum sensing (QS)molecules. As well as affecting the behaviour of bacteria, these QS molecules can cause inflammation in the lung of CF patients. Selective growth of QS-producing organisms can trigger lung exacerbations in CF. If antibiotics kill this population of bacteria and QS molecule levels drop in the lung, patients recover from infection quickly. Failure to kill these bacteria with antibiotics allow QS molecule levels to remain elevated and patients to have prolonged infections.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
We will sequentially recruit patients attending our CF centre with an infective exacerbation of CF, who are chronically infected with Pseudomonas aeruginosa.
We will record spirometry, blood markers of inflammation, quality of life questionnaires and investigate sputum samples for:
- Routine microbiology
- Bacterial diversity using 16s RNA identification techniques
- Relative abundance of P.aeruginosa hypermutators
- Levels of quorum sensing molecules
These observations will be undertaken before commencing intravenous antibiotic therapy, on days 7, 10 and the last day of antibiotic therapy. Patients will also be reviewed one month after the end of antibiotic therapy where spirometry and a sputum sample will be collected for the above investigations.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
London, Royaume-Uni, SW3 6NP
- Department of Cystic Fibrosis, NHLI, Imperial College,
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Confirmed diagnosis of Cystic Fibrosis
- Chronic Pseudomonas aeruginosa
- Symptoms and signs of infective exacerbation
Exclusion Criteria:
- age under 16
- unable to give consent or patients with significant mental health problems
- co-existent active allergic bronchopulmonary aspergillosis requiring a change in steroid or antifungal therapy
- a previous participant in this study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
---|
Cystic Fibrosis, infection
Cystic Fibrosis patients with an infective exacerbation
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Margaret Hodson, MD MSc FRCP, Imperial College London
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11/H0713/7
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .